News
Market Mover
Incyte Acquires Vega Therapeutics for $1.25B to Replace Jakafi Revenue
Suhaib
Executive summary
Incyte is acquiring Vega Therapeutics for $1.25 billion upfront to gain access to VGA039, a late-stage drug for severe von Willebrand disease. The deal aims to offset revenue losses from Jakafi's patent expiration in 2028, with analysts projecting the new drug could generate over $1 billion in annual sales by the early 2030s.
What happened
Incyte announced it will acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront plus up to $750 million in sales milestones. The deal centers on VGA039, a monoclonal antibody currently in Phase 3 trials for treating severe von Willebrand disease, the most common inherited bleeding disorder affecting an estimated 3.2 million Americans. Unlike current treatments requiring two to three infusions weekly, VGA039 would be a monthly subcutaneous injection patients can self-administer. Early trial data showed a 74% reduction in bleeding rates with good tolerability. The transaction is expected to close in the third quarter of 2024.
Why the stock moved
Following the announcement, H.C. Wainwright raised its price target on Incyte to $140, reflecting optimism about the acquisition's strategic fit. Analysts view VGA039 as a relatively de-risked asset that addresses a critical need: replacing revenue from Jakafi, Incyte's top-selling drug generating $3 billion annually, which faces patent expiration starting in 2028. The new drug's projected launch in 2030 aligns closely with Jakafi's loss of exclusivity, potentially filling the revenue gap. With preliminary Phase 3 data expected in early 2029, investors see a clear path to commercialization in a market where prophylactic treatment adoption currently sits at just 25% despite much higher need.
Bigger picture
This marks Incyte's first major acquisition under new CEO Bill Meury and signals the company's strategy to stay anchored in hematology while diversifying beyond Jakafi dependence. The deal draws parallels to Roche's Hemlibra in hemophilia A, where a convenient subcutaneous therapy transformed prophylaxis adoption rates to 90%. Incyte believes VGA039 could similarly expand the von Willebrand prophylaxis market from the current 2,000 treated patients to a potential 7,000 to 10,000 with severe disease. The company estimates VGA039 could surpass $1 billion in global sales, making it a potential blockbuster. With $4 billion in cash remaining post-deal, Incyte retains capacity for additional acquisitions.
What investors watch
Key milestones include the transaction closing in Q3 2024 and preliminary Phase 3 data expected in early 2029. Investors will monitor enrollment progress and safety signals from the ongoing trial, which evaluates bleeding frequency over a 49-week treatment period in patients aged 12 to 75. Commercial execution will depend on Incyte's ability to expand prophylaxis adoption among the estimated 35,000 patients treated in specialty centers. Longer term, watch for potential competition from Hemab Therapeutics' HMB-002, currently in Phase 2 trials for the same indication, and whether Incyte pursues additional deals to further strengthen its post-Jakafi pipeline.
